Xuelian Wei

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman, David Chien Lye, David S.C. Hui et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 723 citations · Full text

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 362 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry et al. · The Lancet · 2012 · 346 citations

Hiv/aids Counselling, Treatment And Prevention, Medicine +12

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 184 citations · Full text